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A case of complex partial status epilepticus (CPSE) with high dose treatment of tiagabine (TGB) is reported. Seizure aggravation
and CPSE developed after stepwise increase of TGB to a dose of 60 mg per day as add-on treatment to carbamazepine (CBZ)
1200 mg/day and vigabatrine (VGB) 1000 mg/day. The EEG during CPSE showed bilateral rhythmic slow activity. Clinical
symptoms of CPSE and the EEG normalized after i.v. treatment with clonazepam. The literature and the possible mechanism of
this paradoxical phenomenon are discussed.
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Paradoxical seizure exacerbation and induction of sta-
tus epilepticus (SE) by conventional epileptic drugs
have been reported for CBZ1, carbamazepine-10, 11-
epoxide (CBZ-E)2 and phenytoin (PHE)3.
Tiagabine (TGB), a nipecotic acid analogue, is a
new antiepileptic drug which inhibits neuronal and
glial GABA uptake4. It is effective in partial seizures
with and without secondary generalization5. Although
TGB has only mild side effects on the central nervous
system6, there are two recent case reports with paradox-
ical aggravation of seizures leading to non-convulsive
status epilepticus7, 8. These findings were contrasted
by the work of Shinnar and co-workers9 who argued
that the incidence of SE in TGB-treated patients is not
higher than the expected incidence in non-TGB-treated
patients in randomized trials and population-based ex-
ternal cohorts10–13. In this report, we describe another
patient with seizure exacerbation and CPSE with TGB
as add-on treatment to CBZ and VGB, discuss the lit-
erature and the possible pathophysiology of this para-
doxical phenomenon.
Case report
A 21-year-old woman presented in a confusional state
with partial responsiveness and complete amnesia for
at least 5 hours. Her symptoms developed while she1059–1311/99/010041 + 04 $12.00/0was on stepwise increase of TGB during the previous
2 months as add-on treatment to VGB 1000 mg/day
and CBZ 1200 mg/day. Two weeks before admission
she was on 30 mg TGB b.i.d. which led to an increase
in seizure frequency from two per month to five per
week. She was admitted to hospital in a confusional
state with partial responsiveness, disturbed balance and
gait ataxia interrupted by short erratic myoclonic jerks
of the extremities. The EEG showed diffuse general-
ized bilateral synchronous slow activity (Fig. 1). Fol-
lowing intravenous infusion of 2 mg clonazepam there
was an instantaneous change of the clinical picture: she
became fully responsive, with cessation of involuntary
movements, normal gait and normalization of the EEG
(Fig. 2). She had complete retrograde amnesia for at
least 5 hours. TGB was withdrawn and clonazepam
2 mg t.i.d. was added to CBZ 1200 mg per day. She
made a complete recovery, experiencing her previous
seizure frequency of about two per month.
She was the third child of healthy parents with
no family history of epilepsy. Pregnancy and birth
were normal and the developmental milestones reached
within the normal limits. At the age of 8, partial seizures
began with clonic jerking of the left leg, which initially
responded well to CBZ leading to total seizure control
from age 15 to 17, followed by a stepwise reduction of
CBZ. During the withdrawal period seizures recurred:
she experienced an aura with the feeling of movement
in the legs without visible jerking, followed by slight
clonic jerking of the left or right leg with preservedc© 1999 British Epilepsy Association
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Fig. 1: EEG during complex partial status epilepticus.
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Fig. 2: EEG after 2 mg clonazepam i.v.consciousness. CBZ was reinstituted but seizures per-
sisted with a frequency of five to 10 per month. The
EEG showed blunt sharp waves over the left frontal
region (Fig. 3).At the age of 18 she experienced seizures with jerk-
ing of both legs during the night with preserved con-
sciousness. CBZ was increased to 1200 mg but seizure
frequency remained high with nocturnal clustering.
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Fig. 3: Interictal EEG with blunt sharp wave activity left frontal.The interictal EEG revealed diffuse slowing with very
infrequent left frontal sharp wave activity. Findings
on magnetic resonance imaging (MRI) were normal,
but interictal Tc99-HMPAO SPECT demonstrated a
decreased signal in the left frontal region. Formal
psychometric testing revealed a below average IQ
of 87 on the Wechsler Scale (HAWIE)14, and speed
performance in the trail matching test15 was below
average.
At 19 years old VGB was added up to 2000 mg
without success. One year later VGB was reduced to
1000 mg and TGB was added, starting with 5 mg b.i.d.
which attenuated her seizure frequency from 10 per
month with nocturnal clustering to 2 per month.
Discussion
The reported patient presented with a prolonged
episode of confusion, partial responsiveness and am-
nesia for at least 5 hours which was diagnosed and con-
firmed by ictal EEG as complex partial status epilepti-
cus. To our knowledge this is the first report of CPSE
with TGB which is documented by EEG. The EEG
findings were consistent with the previously described
highly variable patterns16.
The symptoms occurred during the stepwise increase
of TGB at a dose of 60 mg/day. In the previously re-
ported cases the symptoms occurred at 30 mg/day inone case8, 48 mg/day in one case and 60 mg/day in
two cases7. The co-medication was CBZ in a dose of
1200 mg to 1500 mg/day and lamotrigine (LTG) in a
dose of 100 mg to 400 mg/day in three cases, and PHE
350 mg/day in another case7, 8. In the reported case
the co-medication was CBZ 1200 mg/day and VGB
1000 mg/day.
Shinnar evaluated the incidence of SE and CPSE
in the TGB-treated patients of all clinical trials9. In
the placebo-controlled trials, the overall incidence of
CPSE was similar in the TGB-treated patients and the
placebo control group (0.2% vs. 0.0%). However, in the
monotherapy studies, the high dose treatment group on
36 mg/day experienced more CPSE than the low dose
treatment group on 6 mg/day (4% vs. 0%, P D 0:054).
None of these patients received as high dosage levels as
four of the five reported patients with CPSE including
the presented one (48 mg to 60 mg/day). In addition
to that, the presented case received VGB, which en-
hances GABA-ergic activity by blocking the GABA-
transaminase17.
In one study of CPSE, the most common precip-
itants were generalized tonic–clonic seizures (GTC)
and changes in antiepileptic drugs, either because of
non-compliance or under medical direction18. Only in
case one of Schapel’s series7 was there a discontinu-
ation of CBZ, which could have led to an increase in
seizure frequency and CPSE, despite its cautious rate
of withdrawal.
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tory, 1986.
16. }Shorvon, S. D. Status Epilepticus: Its Clinical Features and
Treatment in Children and Adults. Cambridge, Cambridge Uni-
versity Press, 1994.
17. }Lippert, B., Metcalf, B. W., Jung, M. J. and Casara, P. 4-
Amino-hex-5-enoic acide, a selective catalytic inhibitor of 4-
aminobutyric acid aminotransferase in mammalian brain. Eu-
ropean Journal of Biochemistry 1977; 74: 441–445.
18. }Tomson, T., Lindblom, U., Nilsson, B. Y. Non-convulsive sta-
tus epilepticus in adults: thirty-two consecutive patients from aA recent study related CPSE to increased of CBZ-
E secondary to co-medication2. Gustavson and co-
workers showed that TGB caused no significant
changes in CBZ or CBZ-E levels when added under
steady-state pharmacokinetics19.
At the neurochemical level, abrupt withdrawal of
GABA-ergic activity may result in generalized con-
vulsions or electrographic activity in animals20. TGB
acts as a specific GABA-uptake inhibitor thereby
enhancing GABA-ergic activity. TGB is 2.5 times
more potent in inhibiting glial, as opposed to neu-
ronal, GABA uptake21. At high doses TGB may block
all GABA uptake and therefore depleting intracellu-
lar GABA possibly leading to an attenuation of the
anticonvulsant properties of TGB. In animal exper-
iments TGB shows a biphasic dose–response curve
against methyl-6,7-dimethoxy-4-ethyl-B-carboline-3-
carboxylate (DMCM)-induced clonic convulsions (in
mice) and pentylenetetrazol (PTZ)-induced clonic and
tonic convulsions (in mice and rats) with an attenu-
ated anticonvulsant effect at higher doses22. However,
TGB lacks proconvulsant or convulsant activity even
in doses up to 100 mg/kg i.p. in chemically kindled
mice4. To date, the mechanism of seizure exacerbation
by TGB seems unclear.
In summary, we reported the clinical and EEG find-
ings of a patient, who developed CPSE with TGB and
want to draw attention to the possible seizure precipi-
tating effect of TGB in high doses of more than 40 mg
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